Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Ismidenon by AmyriAD Therapeutics for Alzheimer's Disease: Likelihood of Approval
Ismidenon is under clinical development by AmyriAD Therapeutics and currently in Phase II for Alzheimer's Disease. According to GlobalData, Phase...